Pharmacoeconomic report: Dupilumab (Dupixent) (Sanofi Genzyme, a division of Sanofi-aventis Canada Inc.) indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dupliumab (Dupixent) is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The recommended dose of dupilumab is age- and we...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, June 2020
Edition:	Final (with redactions)
Series:	CADTH drug reimbursement review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK566135
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa